Depression Programs Bring in Good Money for Naurex, Prexa
By Catherine Shaffer
Thursday, May 12, 2011
CNS company Naurex Inc., of Evanston Ill., completed an $18 million Series A financing for Phase II trials of its lead depression compound, GLYX-13. At the same time, Prexa Pharmaceuticals, of Boston, landed a $7 million Series B to advance triple reuptake inhibitor PRX-12251 into Phase Ib.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.